EUCTR2014-001785-95-BG进行中（未招募）1 期
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection. - Phase 2 Asthma
Biota Pharmaceuticals, Inc.0 个研究点目标入组 480 人开始时间: 2015年1月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male and female subjects, aged 18-75 years inclusive, with an established clinical history of asthma for at least one year in accordance with the definitions described by the GINA guidelines (GINA 20121 or the National Asthma Education and Prevention NAEP Diagnosis Guidelines 20072);
- •2) History within the previous 14 months (prior to screening) of asthma worsening or exacerbation due to presumed viral respiratory infection which required asthma rescue medication treatment;
- •3) Subject has moderate or severe asthma defined by their current medication regimen of taking at least a medium-dose or high-dose inhaled corticosteroid (ICS) defined as fluticasone at a dosage of at least > 264 mcg daily (or equivalent dose for other inhaled ICS). The subject's asthma medication regimen has been stable for at least 4 weeks prior to screening and for at least 2 weeks prior to Study Day 1;
- •4) Subject has at screening, or within the prior year, documented variable airway obstruction as indicated by an increase in FEV1 (>or= 12%) to short-acting bronchodilator, or positive methacholine challenge, or positive histamine challenge (PC20 <8mg/ml). For subjects without appropriate documentation at screening, or within the prior year, the procedure to document the increase in FEV1 may be performed within 3 days following the Screening Visit;
- •5) Capable of giving written informed consent that includes compliance with the requirements and restrictions listed in the consent form. Note: signed informed consent must be on file prior to screening procedures;
- •6) Subject is able to understand and comply with the protocol requirements, instructions and restrictions and complete the study questionnaires in a written language they understand;
- •7) Female subjects who are not postmenopausal for at least 2 years or surgically sterile with complete hysterectomy or bilateral oophorectomy and male subjects, who are not surgically sterile via vasectomy, must agree to use a double barrier method of birth control, such as, a condom plus spermicidal agent (foam/gel/film/cream/suppository) from the time of randomization until 30 days after completion of study drug dosing. This includes female subjects who are using hormonal contraception. Male subjects cannot donate sperm during the study starting at day 1 and for 90 days after completion of study drug dosing.
- •8) Female subjects must not be breastfeeding or pregnant.
- •Subjects must continue to meet the previous criteria and additionally meet the following criteria at Study Day 1 in order to be eligible for randomization and study treatment:
- •a) Subject presents to clinic reporting symptoms of a cold (e.g., answers yes to the question, Do you have a cold today?”) with onset such that they can be randomized and dosed preferably within 24 hours but up to a 48 hour interval from symptom onset to study treatment;
- •b) Subject is qualified for presumptive human rhinovirus infection by clinical exam, and the presence of each of the following Day 1 WURSS-21 symptoms at a severity of 2 or greater: runny nose, sore throat, scratchy throat, as well as a minimum WURSS-21 total symptom score on day 1 of at least 20 points;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 456
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •1) Positive result for influenza rapid-antigen test performed on Study Day 1;
- •2) A fever on Day 1 of 100.4°F (38°C) or greater;
- •3) Subject presents at clinic on Study Day 1 with severe asthma exacerbation defined as requiring immediate treatment with systemic corticosteroids or increased doses of inhaled corticosteroids;
- •4) Use of systemic steroids within 30 days before Study Day 1;
- •5) Current use of theophylline at Screening or within 4 days of Study Day 1 and any use throughout the duration of the study;
- •6) Subjects with evidence of a lower respiratory infection at Study Day 1, and/or a history or current evidence of chronic obstructive airways disease, cystic fibrosis, or chronic sinusitis;
- •7) A medical history or current clinical evidence of significant hematological, gastrointestinal, renal, hepatic, cerebrovascular, immunologic, psychiatric or cardiovascular disease or event (including uncontrolled hypertension as determined by the Investigator), or any clinical condition, that may in the opinion of the Investigator or Medical Monitor, impact on the subject's ability to participate in the study, the subject's safety, or on the study results;
- •8) History of adverse reaction or hypersensitivity to capsid binders, or history of significant seasonal allergy within the last 3 years that in the opinion of the investigator would significantly interfere with the evaluation of asthma control or diagnosis of presumptive HRV infection;
- •9)Clinical laboratory values at screening for neutrophils which reflect grade 2 or higher reductions from normal range, or AST or ALT results which reflect grade 2 or higher elevations per the Common Terminology
- •Criteria for Adverse Events (CTCAE). Screening hemoglobin value reductions of >2 gm/dL below Lower Limit of Normal (LLN). Subjects with other clinical laboratory abnormalities outside normal reference ranges will be considered for inclusion, if in the opinion of the investigator or Medical Monitor the abnormalities are not clinically significant, and will not jeopardize the safety of the subject or the validity of the study;
- •10) Use of cold preparations, nasal lavage preparations or sprays, or prescription or over-the-counter nasal decongestants within the 24 hours preceding completion of the Day 1 WURSS-21 and randomization and during the study. Episodic use of over-the-counter anti-cholinergics is excluded within the 24 hours preceding completion of the Day 1 WURSS-21 and randomization and during the study. Use of nasal antihistamines
- •is excluded for 3 days prior to randomization and during the study. Use of the anti-histamines acrivastine, brompheniramine, chorpheniramine, dimenhydrinate, and doxylamine are excluded prior to
- •randomization on Day 1 (short-acting for 1 week and long-acting for 2 weeks) and during the study. Note: The use of new generation antihistamines, e.g. loratadine, cetirizine, desloratadine, fexofenadine, and levocetirizine, and nasal steroid preparations is allowed, if use is stable for 7 days prior to Study Day 1 and continues in a stable regimen throughout the study. Acetaminophen and NSAID use is allowed.
- •11) Current (at screening and Study Day 1) abuse of alcohol or any use illicit drugs, or history of alcohol or illicit drug abuse within the preceding 2 years. Any use of marijuana within 48 hours of Day 1 and at
- •any time during the study, unless being used for a prescribed medical reason where the medical reason itself is not exclusionary;
- •12) A positive pregnancy test at
研究者
相似试验
尚未招募
2 期
Efficacy and Safety of Afimetoran compared with Placebo in Participants with Active Systemic Lupus ErythematosusCTRI/2024/01/061756BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED
已完成
2 期
A Study of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-infected with Hepatitis B and Hepatitis D VirusJPRN-jRCT2071200049akama Takahiro190
进行中（未招募）
1 期
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects with Moderate to Severe, Active Rheumatoid Arthritis with Inadequate Response or Intolerance to at Least One Biologic Disease modifying Anti-rheumatic Drug or a Janus Kinase InhibitorRheumatoid arthritis (RA)MedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2022-000169-42-BGKiniksa Pharmaceuticals, Ltd.131
进行中（未招募）
不适用
A Phase 2, Multicenter, Randomized, Double-blind, Placebo controlled Trial of CNTO 1275, a Fully Human Anti IL 12 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic ArthritisPsoriatic ArthritisEUCTR2005-003525-92-FICentocor B.V.140
进行中（未招募）
1 期
A study to assess whether ZS (Sodium Zirconium Cyclosilicate) added to standard of care (insulin and glucose) is effective in treating elevated blood potassium concentratioHyperkalemia requiring urgent therapy (serum potassium more than or equal to 5.8mmol/L).MedDRA version: 20.1 Level: PT Classification code 10020646 Term: Hyperkalaemia System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-003955-50-DKAstraZeneca, AB132